Dysfunctional high-density lipoproteins in coronary heart disease: implications for diagnostics and therapy

Translational Research

Volumn 173, Issue , 2016, Pages 30-57

  Annema, Wijtske ^a   von Eckardstein, Arnold ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 ANTIBODY; APOLIPOPROTEIN C3; AUTOANTIBODY; BIOLOGICAL MARKER; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; FIBRIC ACID DERIVATIVE; GLYCEROPHOSPHOLIPID; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MICRORNA; MYELOPEROXIDASE; NICOTINIC ACID; PROTEIN ANTIBODY; SERUM AMYLOID A; SPHINGOLIPID; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; CHOLESTEROL;

CARBAMOYLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL EFFLUX; HUMAN; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MODIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CORONARY ARTERY DISEASE; METABOLISM; RISK FACTOR;

AUTOANTIBODIES; BIOMARKERS; CHOLESTEROL; CORONARY ARTERY DISEASE; HUMANS; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 84961226906     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.02.008     Document Type: Review

References (244)

1. 1 Cholesterol Treatment Trialists Collaboration, Fulcher, J., O'Connell, R., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385 (2015), 1397–1405.
2. 2 Emerging Risk Factors Collaboration, Di Angelantonio, E., Sarwar, N., et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302 (2009), 1993–2000.
3. 3 Hoekstra, M., Van Eck, M., Mouse models of disturbed HDL metabolism. Handb Exp Pharmacol 224 (2015), 301–336.
4. 4 Luscher, T.F., Landmesser, U., von Eckardstein, A., Fogelman, A.M., High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ Res 114 (2014), 171–182.
5. 5 Annema, W., von Eckardstein, A., High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 77 (2013), 2432–2448.
6. 6 Voight, B.F., Peloso, G.M., Orho-Melander, M., et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380 (2012), 572–580.
7. 7 Darabi, M., Guillas-Baudouin, I., Le Goff, W., Chapman, M.J., Kontush, A., Therapeutic applications of reconstituted HDL: when structure meets function. Pharmacol Ther 157 (2016), 28–42.
8. 8 Kontush, A., Lindahl, M., Lhomme, M., et al. Structure of HDL: particle subclasses and molecular components. Handb Exp Pharmacol 224 (2015), 3–51.
9. 9 Vickers, K.C., Palmisano, B.T., Shoucri, B.M., Shamburek, R.D., Remaley, A.T., MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 13 (2011), 423–433.
10. 10 Wagner, J., Riwanto, M., Besler, C., et al. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol 33 (2013), 1392–1400.
11. 11 Riwanto, M., Landmesser, U., High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res 54 (2013), 3227–3243.
12. 12 Besler, C., Luscher, T.F., Landmesser, U., Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med 4 (2012), 251–268.
13. 13 Annema, W., von Eckardstein, A., Kovanen, P.T., HDL and atherothrombotic vascular disease. Handb Exp Pharmacol 224 (2015), 369–403.
14. 14 Cuchel, M., Rader, D.J., Macrophage reverse cholesterol transport: key to the regression of atherosclerosis?. Circulation 113 (2006), 2548–2555.
15. 15 Annema, W., Tietge, U.J., Regulation of reverse cholesterol transport—a comprehensive appraisal of available animal studies. Nutr Metab (Lond), 9, 2012, 25.
16. 16 Navab, M., Hama, S.Y., Anantharamaiah, G.M., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res 41 (2000), 1495–1508.
17. 17 Navab, M., Hama, S.Y., Cooke, C.J., et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41 (2000), 1481–1494.
18. 18 Kontush, A., Chantepie, S., Chapman, M.J., Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 23 (2003), 1881–1888.
19. 19 Watson, A.D., Berliner, J.A., Hama, S.Y., et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995), 2882–2891.
20. 20 Nofer, J.R., van der Giet, M., Tolle, M., et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 113 (2004), 569–581.
21. 21 Riwanto, M., Rohrer, L., Roschitzki, B., et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation 127 (2013), 891–904.
22. 22 de Souza, J.A., Vindis, C., Negre-Salvayre, A., et al. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 14 (2010), 608–620.
23. 23 Argraves, K.M., Gazzolo, P.J., Groh, E.M., et al. High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function. J Biol Chem 283 (2008), 25074–25081.
24. 24 Wilkerson, B.A., Grass, G.D., Wing, S.B., Argraves, W.S., Argraves, K.M., Sphingosine 1-phosphate (S1P) carrier-dependent regulation of endothelial barrier: high density lipoprotein (HDL)-S1P prolongs endothelial barrier enhancement as compared with albumin-S1P via effects on levels, trafficking, and signaling of S1P1. J Biol Chem 287 (2012), 44645–44653.
25. 25 Seetharam, D., Mineo, C., Gormley, A.K., et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res 98 (2006), 63–72.
26. 26 Zhu, W., Saddar, S., Seetharam, D., et al. The scavenger receptor class B type I adaptor protein PDZK1 maintains endothelial monolayer integrity. Circ Res 102 (2008), 480–487.
27. 27 Cockerill, G.W., Rye, K.A., Gamble, J.R., Vadas, M.A., Barter, P.J., High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995), 1987–1994.
28. 28 Nicholls, S.J., Dusting, G.J., Cutri, B., et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 111 (2005), 1543–1550.
29. 29 Murphy, A.J., Woollard, K.J., Hoang, A., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 28 (2008), 2071–2077.
30. 30 Bursill, C.A., Castro, M.L., Beattie, D.T., et al. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 30 (2010), 1773–1778.
31. 31 Tolle, M., Pawlak, A., Schuchardt, M., et al. HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol 28 (2008), 1542–1548.
32. 32 Calkin, A.C., Drew, B.G., Ono, A., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 120 (2009), 2095–2104.
33. 33 Nofer, J.R., Walter, M., Kehrel, B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 18 (1998), 861–869.
34. 34 Brodde, M.F., Korporaal, S.J., Herminghaus, G., et al. Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI: role of negatively charged phospholipids. Atherosclerosis 215 (2011), 374–382.
35. 35 Griffin, J.H., Kojima, K., Banka, C.L., Curtiss, L.K., Fernandez, J.A., High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 103 (1999), 219–227.
36. 36 Sugatani, J., Miwa, M., Komiyama, Y., Ito, S., High-density lipoprotein inhibits the synthesis of platelet-activating factor in human vascular endothelial cells. J Lipid Mediat Cell Signal 13 (1996), 73–88.
37. 37 Viswambharan, H., Ming, X.F., Zhu, S., et al. Reconstituted high-density lipoprotein inhibits thrombin-induced endothelial tissue factor expression through inhibition of RhoA and stimulation of phosphatidylinositol 3-kinase but not Akt/endothelial nitric oxide synthase. Circ Res 94 (2004), 918–925.
38. 38 Oslakovic, C., Krisinger, M.J., Andersson, A., et al. Anionic phospholipids lose their procoagulant properties when incorporated into high density lipoproteins. J Biol Chem 284 (2009), 5896–5904.
39. 39 Riwanto, M., Rohrer, L., von Eckardstein, A., Landmesser, U., Dysfunctional HDL: from structure-function-relationships to biomarkers. Handb Exp Pharmacol 224 (2015), 337–366.
40. 40 Besler, C., Heinrich, K., Rohrer, L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 121 (2011), 2693–2708.
41. 41 Speer, T., Rohrer, L., Blyszczuk, P., et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of toll-like receptor-2. Immunity 38 (2013), 754–768.
42. 42 Kim, J.B., Hama, S., Hough, G., et al. Heart failure is associated with impaired anti-inflammatory and antioxidant properties of high-density lipoproteins. Am J Cardiol 112 (2013), 1770–1777.
43. 43 Patel, P.J., Khera, A.V., Wilensky, R.L., Rader, D.J., Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 15 (2013), 1215–1219.
44. 44 Singh, N., Jacobs, F., Rader, D.J., et al. Impaired cholesterol efflux capacity and vasculoprotective function of high-density lipoprotein in heart transplant recipients. J Heart Lung Transplant 33 (2014), 499–506.
45. 45 Sviridov, D., Chin-Dusting, J., Nestel, P., et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 81 (2006), 361–366.
46. 46 Bellanger, N., Orsoni, A., Julia, Z., et al. Atheroprotective reverse cholesterol transport pathway is defective in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 31 (2011), 1675–1681.
47. 47 Ottestad, I.O., Halvorsen, B., Balstad, T.R., et al. Triglyceride-rich HDL3 from patients with familial hypercholesterolemia are less able to inhibit cytokine release or to promote cholesterol efflux. J Nutr 136 (2006), 877–881.
48. 48 Balstad, T.R., Holven, K.B., Ottestad, I.O., et al. Altered composition of HDL3 in FH subjects causing a HDL subfraction with less atheroprotective function. Clin Chim Acta 359 (2005), 171–178.
49. 49 Khera, A.V., Cuchel, M., de la Llera-Moya, M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364 (2011), 127–135.
50. 50 Li, X.M., Tang, W.H., Mosior, M.K., et al. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33 (2013), 1696–1705.
51. 51 Rohatgi, A., Khera, A., Berry, J.D., et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371 (2014), 2383–2393.
52. 52 Ritsch, A., Scharnagl, H., Marz, W., HDL cholesterol efflux capacity and cardiovascular events. N Engl J Med 372 (2015), 1870–1871.
53. 53 Saleheen, D., Scott, R., Javad, S., et al. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol 3 (2015), 507–513.
54. 54 Annema, W., Dikkers, A., de Boer, J.F., et al. HDL cholesterol efflux predicts graft failure in renal transplant recipients. J Am Soc Nephrol 27 (2016), 595–603.
55. 55 Alwaili, K., Bailey, D., Awan, Z., et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 1821 (2012), 405–415.
56. 56 Clifton, P.M., Mackinnon, A.M., Barter, P.J., Effects of serum amyloid A protein (SAA) on composition, size, and density of high density lipoproteins in subjects with myocardial infarction. J Lipid Res 26 (1985), 1389–1398.
57. 57 Coetzee, G.A., Strachan, A.F., van der Westhuyzen, D.R., et al. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem 261 (1986), 9644–9651.
58. 58 Banka, C.L., Yuan, T., de Beer, M.C., et al. Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. J Lipid Res 36 (1995), 1058–1065.
59. 59 van der Westhuyzen, D.R., Cai, L., de Beer, M.C., de Beer, F.C., Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J Biol Chem 280 (2005), 35890–35895.
60. 60 Artl, A., Marsche, G., Lestavel, S., Sattler, W., Malle, E., Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 20 (2000), 763–772.
61. 61 Vaisar, T., Tang, C., Babenko, I., et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res 56 (2015), 1519–1530.
62. 62 Annema, W., Nijstad, N., Tolle, M., et al. Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 51 (2010), 743–754.
63. 63 Cai, L., de Beer, M.C., de Beer, F.C., van der Westhuyzen, D.R., Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J Biol Chem 280 (2005), 2954–2961.
64. 64 Tolle, M., Huang, T., Schuchardt, M., et al. High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovasc Res 94 (2012), 154–162.
65. 65 Zewinger, S., Drechsler, C., Kleber, M.E., et al. Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. Eur Heart J 36 (2015), 3007–3016.
66. 66 Ashby, D., Gamble, J., Vadas, M., et al. Lack of effect of serum amyloid A (SAA) on the ability of high-density lipoproteins to inhibit endothelial cell adhesion molecule expression. Atherosclerosis 154 (2001), 113–121.
67. 67 Van Lenten, B.J., Hama, S.Y., de Beer, F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96 (1995), 2758–2767.
68. 68 Chiba, T., Chang, M.Y., Wang, S., et al. Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans. Arterioscler Thromb Vasc Biol 31 (2011), 1326–1332.
69. 69 Vaisar, T., Mayer, P., Nilsson, E., et al. HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta 411 (2010), 972–979.
70. 70 Xiong, X., Liu, H., Hua, L., et al. The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis, 14, 2015, 127.
71. 71 Chang, P.Y., Lee, C.M., Hsu, H.C., et al. Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: the Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan. Lipids Health Dis, 11, 2012, 162.
72. 72 Kavo, A.E., Rallidis, L.S., Sakellaropoulos, G.C., et al. Qualitative characteristics of HDL in young patients of an acute myocardial infarction. Atherosclerosis 220 (2012), 257–264.
73. 73 Jensen, M.K., Rimm, E.B., Furtado, J.D., Sacks, F.M., Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J Am Heart Assoc, 1, 2012 jah3-e000232.
74. 74 TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute, Crosby, J., et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med 371 (2014), 22–31.
75. 75 Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Tybjaerg-Hansen, A., Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med 371 (2014), 32–41.
76. 76 von Eckardstein, A., Holz, H., Sandkamp, M., et al. Apolipoprotein C-III (Lys58–Glu). Identification of an apolipoprotein C-III variant in a family with hyperalphalipoproteinemia. J Clin Invest 87 (1991), 1724–1731.
77. 77 Kawakami, A., Aikawa, M., Libby, P., et al. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation 113 (2006), 691–700.
78. 78 Kontush, A., Lhomme, M., Chapman, M.J., Unraveling the complexities of the HDL lipidome. J Lipid Res 54 (2013), 2950–2963.
79. 79 Papathanasiou, A., Kostara, C., Cung, M.T., et al. Analysis of the composition of plasma lipoproteins in patients with extensive coronary heart disease using 1H NMR spectroscopy. Hellenic J Cardiol 49 (2008), 72–78.
80. 80 Pruzanski, W., Stefanski, E., de Beer, F.C., et al. Comparative analysis of lipid composition of normal and acute-phase high density lipoproteins. J Lipid Res 41 (2000), 1035–1047.
81. 81 Fournier, N., Francone, O., Rothblat, G., et al. Enhanced efflux of cholesterol from ABCA1-expressing macrophages to serum from type IV hypertriglyceridemic subjects. Atherosclerosis 171 (2003), 287–293.
82. 82 Attia, N., Ramaharo, A., Paul, J.L., et al. Enhanced removal of cholesterol from macrophage foam cells to serum from type IV hypertriglyceridemic subjects. Atherosclerosis 198 (2008), 49–56.
83. 83 Julia, Z., Duchene, E., Fournier, N., et al. Postprandial lipemia enhances the capacity of large HDL2 particles to mediate free cholesterol efflux via SR-BI and ABCG1 pathways in type IIB hyperlipidemia. J Lipid Res 51 (2010), 3350–3358.
84. 84 Posadas-Sanchez, R., Posadas-Romero, C., Mendoza-Perez, E., et al. Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl. Am J Cardiol 109 (2012), 636–641.
85. 85 Greene, D.J., Skeggs, J.W., Morton, R.E., Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI). J Biol Chem 276 (2001), 4804–4811.
86. 86 Camont, L., Lhomme, M., Rached, F., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33 (2013), 2715–2723.
87. 87 Lan Hsia, S., Duncan, R., Schob, A.H., et al. Serum levels of high-density lipoprotein phospholipids correlate inversely with severity of angiographically defined coronary artery disease. Atherosclerosis 152 (2000), 469–473.
88. 88 Piperi, C., Kalofoutis, C., Papaevaggeliou, D., et al. The significance of serum HDL phospholipid levels in angiographically defined coronary artery disease. Clin Biochem 37 (2004), 377–381.
89. 89 Sutter, I., Velagapudi, S., Othman, A., et al. Plasmalogens of high-density lipoproteins (HDL) are associated with coronary artery disease and anti-apoptotic activity of HDL. Atherosclerosis 241 (2015), 539–546.
90. 90 Rached, F., Lhomme, M., Camont, L., et al. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infarction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim Biophys Acta 1851 (2015), 1254–1261.
91. 91 Zerrad-Saadi, A., Therond, P., Chantepie, S., et al. HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 29 (2009), 2169–2175.
92. 92 Yancey, P.G., de la Llera-Moya, M., Swarnakar, S., et al. High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 275 (2000), 36596–36604.
93. 93 Yancey, P.G., Kawashiri, M.A., Moore, R., et al. In vivo modulation of HDL phospholipid has opposing effects on SR-BI- and ABCA1-mediated cholesterol efflux. J Lipid Res 45 (2004), 337–346.
94. 94 Davidson, W.S., Gillotte, K.L., Lund-Katz, S., et al. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J Biol Chem 270 (1995), 5882–5890.
95. 95 Baker, P.W., Rye, K.A., Gamble, J.R., Vadas, M.A., Barter, P.J., Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 41 (2000), 1261–1267.
96. 96 Agarwala, A.P., Rodrigues, A., Risman, M., et al. High-density lipoprotein (HDL) phospholipid content and cholesterol efflux capacity are reduced in patients with very high HDL cholesterol and coronary disease. Arterioscler Thromb Vasc Biol 35 (2015), 1515–1519.
97. 97 Braverman, N.E., Moser, A.B., Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 1822 (2012), 1442–1452.
98. 98 Jurgens, G., Fell, A., Ledinski, G., Chen, Q., Paltauf, F., Delay of copper-catalyzed oxidation of low density lipoprotein by in vitro enrichment with choline or ethanolamine plasmalogens. Chem Phys Lipids 77 (1995), 25–31.
99. 99 Reiss, D., Beyer, K., Engelmann, B., Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J 323:Pt 3 (1997), 807–814.
100. 100 Schwendeman, A., Sviridov, D.O., Yuan, W., et al. The effect of phospholipid composition of reconstituted HDL on its cholesterol efflux and anti-inflammatory properties. J Lipid Res 56 (2015), 1727–1737.
101. 101 Horter, M.J., Sondermann, S., Reinecke, H., et al. Associations of HDL phospholipids and paraoxonase activity with coronary heart disease in postmenopausal women. Acta Physiol Scand 176 (2002), 123–130.
102. 102 Christoffersen, C., Obinata, H., Kumaraswamy, S.B., et al. Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci U S A 108 (2011), 9613–9618.
103. 103 Sutter, I., Park, R., Othman, A., et al. Apolipoprotein M modulates erythrocyte efflux and tubular reabsorption of sphingosine-1-phosphate. J Lipid Res 55 (2014), 1730–1737.
104. 104 Kimura, T., Sato, K., Kuwabara, A., et al. Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells. J Biol Chem 276 (2001), 31780–31785.
105. 105 Kimura, T., Sato, K., Malchinkhuu, E., et al. High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors. Arterioscler Thromb Vasc Biol 23 (2003), 1283–1288.
106. 106 Kimura, T., Tomura, H., Mogi, C., et al. Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells. J Biol Chem 281 (2006), 37457–37467.
107. 107 Galvani, S., Sanson, M., Blaho, V.A., et al. HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal, 8, 2015, ra79.
108. 108 Argraves, K.M., Sethi, A.A., Gazzolo, P.J., et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis, 10, 2011, 70.
109. 109 Matsuo, Y., Miura, S., Kawamura, A., et al. Newly developed reconstituted high-density lipoprotein containing sphingosine-1-phosphate induces endothelial tube formation. Atherosclerosis 194 (2007), 159–168.
110. 110 Tamama, K., Tomura, H., Sato, K., et al. High-density lipoprotein inhibits migration of vascular smooth muscle cells through its sphingosine 1-phosphate component. Atherosclerosis 178 (2005), 19–23.
111. 111 Tao, R., Hoover, H.E., Honbo, N., et al. High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 298 (2010), H1022–H1028.
112. 112 Brulhart-Meynet, M.C., Braunersreuther, V., Brinck, J., et al. Improving reconstituted HDL composition for efficient post-ischemic reduction of ischemia reperfusion injury. PLoS One, 10, 2015, e0119664.
113. 113 Theilmeier, G., Schmidt, C., Herrmann, J., et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 114 (2006), 1403–1409.
114. 114 Karuna, R., Park, R., Othman, A., et al. Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism. Atherosclerosis 219 (2011), 855–863.
115. 115 Sattler, K.J., Elbasan, S., Keul, P., et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 105 (2010), 821–832.
116. 116 Sattler, K., Graler, M., Keul, P., et al. Defects of high-density lipoproteins in coronary artery disease caused by low sphingosine-1-phosphate content: correction by sphingosine-1-phosphate-loading. J Am Coll Cardiol 66 (2015), 1470–1485.
117. 117 Sattler, K., Lehmann, I., Graler, M., et al. HDL-bound sphingosine 1-phosphate (S1P) predicts the severity of coronary artery atherosclerosis. Cell Physiol Biochem 34 (2014), 172–184.
118. 118 Jing, X.D., Wei, X.M., Deng, S.B., et al. The relationship between the high-density lipoprotein (HDL)-associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta 446 (2015), 248–252.
119. 119 Gomaraschi, M., Ossoli, A., Favari, E., et al. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc Res 100 (2013), 36–43.
120. 120 Vickers, K.C., Landstreet, S.R., Levin, M.G., et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci U S A 111 (2014), 14518–14523.
121. 121 Tabet, F., Vickers, K.C., Cuesta Torres, L.F., et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun, 5, 2014, 3292.
122. 122 Shao, B., Oda, M.N., Oram, J.F., Heinecke, J.W., Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein. Chem Res Toxicol 23 (2010), 447–454.
123. 123 Brennan, M.L., Penn, M.S., Van Lente, F., et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 349 (2003), 1595–1604.
124. 124 Rudolph, V., Keller, T., Schulz, A., et al. Diagnostic and prognostic performance of myeloperoxidase plasma levels compared with sensitive troponins in patients admitted with acute onset chest pain. Circ Cardiovasc Genet 5 (2012), 561–568.
125. 125 Zheng, L., Nukuna, B., Brennan, M.L., et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 114 (2004), 529–541.
126. 126 Pennathur, S., Bergt, C., Shao, B., et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 279 (2004), 42977–42983.
127. 127 Bergt, C., Pennathur, S., Fu, X., et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 101 (2004), 13032–13037.
128. 128 Shao, B., Pennathur, S., Heinecke, J.W., Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 287 (2012), 6375–6386.
129. 129 Zheng, L., Settle, M., Brubaker, G., et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem 280 (2005), 38–47.
130. 130 DiDonato, J.A., Aulak, K., Huang, Y., et al. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem 289 (2014), 10276–10292.
131. 131 Huang, Y., DiDonato, J.A., Levison, B.S., et al. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 20 (2014), 193–203.
132. 132 Shao, B., Tang, C., Heinecke, J.W., Oram, J.F., Oxidation of apolipoprotein A-I by myeloperoxidase impairs the initial interactions with ABCA1 required for signaling and cholesterol export. J Lipid Res 51 (2010), 1849–1858.
133. 133 Undurti, A., Huang, Y., Lupica, J.A., et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 284 (2009), 30825–30835.
134. 134 Shao, B., Oda, M.N., Bergt, C., et al. Myeloperoxidase impairs ABCA1-dependent cholesterol efflux through methionine oxidation and site-specific tyrosine chlorination of apolipoprotein A-I. J Biol Chem 281 (2006), 9001–9004.
135. 135 Shao, B., Tang, C., Sinha, A., et al. Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res 114 (2014), 1733–1742.
136. 136 Shao, B., Cavigiolio, G., Brot, N., Oda, M.N., Heinecke, J.W., Methionine oxidation impairs reverse cholesterol transport by apolipoprotein A-I. Proc Natl Acad Sci U S A 105 (2008), 12224–12229.
137. 137 Hewing, B., Parathath, S., Barrett, T., et al. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice. Arterioscler Thromb Vasc Biol 34 (2014), 779–789.
138. 138 Verbrugge, F.H., Tang, W.H., Hazen, S.L., Protein carbamylation and cardiovascular disease. Kidney Int 88 (2015), 474–478.
139. 139 Wang, Z., Nicholls, S.J., Rodriguez, E.R., et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 13 (2007), 1176–1184.
140. 140 Holzer, M., Gauster, M., Pfeifer, T., et al. Protein carbamylation renders high-density lipoprotein dysfunctional. Antioxid Redox Signal 14 (2011), 2337–2346.
141. 141 Holzer, M., Zangger, K., El-Gamal, D., et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein. Antioxid Redox Signal 17 (2012), 1043–1052.
142. 142 Gore, M.O., Luneburg, N., Schwedhelm, E., et al. Symmetrical dimethylarginine predicts mortality in the general population: observations from the Dallas heart study. Arterioscler Thromb Vasc Biol 33 (2013), 2682–2688.
143. 143 Siegerink, B., Maas, R., Vossen, C.Y., et al. Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. Clin Res Cardiol 102 (2013), 193–202.
144. 144 Shih, D.M., Gu, L., Xia, Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998), 284–287.
145. 145 Tward, A., Xia, Y.R., Wang, X.P., et al. Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106 (2002), 484–490.
146. 146 Huang, Y., Wu, Z., Riwanto, M., et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 123 (2013), 3815–3828.
147. 147 Morgantini, C., Meriwether, D., Baldi, S., et al. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 24 (2014), 594–599.
148. 148 Dinu, A.R., Merrill, J.T., Shen, C., et al. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus 7 (1998), 355–360.
149. 149 Vuilleumier, N., Reber, G., James, R., et al. Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardiovascular disease. J Autoimmun 23 (2004), 353–360.
150. 150 Vuilleumier, N., Charbonney, E., Fontao, L., et al. Anti-(apolipoprotein A-1) IgGs are associated with high levels of oxidized low-density lipoprotein in acute coronary syndrome. Clin Sci (Lond) 115 (2008), 25–33.
151. 151 Montecucco, F., Vuilleumier, N., Pagano, S., et al. Anti-apolipoprotein A-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. Eur Heart J 32 (2011), 412–421.
152. 152 Keller, P.F., Pagano, S., Roux-Lombard, P., et al. Autoantibodies against apolipoprotein A-1 and phosphorylcholine for diagnosis of non-ST-segment elevation myocardial infarction. J Intern Med 271 (2012), 451–462.
153. 153 Vuilleumier, N., Bas, S., Pagano, S., et al. Anti-apolipoprotein A-1 IgG predicts major cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 62 (2010), 2640–2650.
154. 154 Pagano, S., Satta, N., Werling, D., et al. Anti-apolipoprotein A-1 IgG in patients with myocardial infarction promotes inflammation through TLR2/CD14 complex. J Intern Med 272 (2012), 344–357.
155. 155 Montecucco, F., Braunersreuther, V., Burger, F., et al. Anti-apoA-1 auto-antibodies increase mouse atherosclerotic plaque vulnerability, myocardial necrosis and mortality triggering TLR2 and TLR4. Thromb Haemost 114 (2015), 410–422.
156. 156 Vuilleumier, N., Rossier, M.F., Pagano, S., et al. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. Eur Heart J 31 (2010), 815–823.
157. 157 Vuilleumier, N., Montecucco, F., Spinella, G., et al. Serum levels of anti-apolipoprotein A-1 auto-antibodies and myeloperoxidase as predictors of major adverse cardiovascular events after carotid endarterectomy. Thromb Haemost 109 (2013), 706–715.
158. 158 Quercioli, A., Montecucco, F., Galan, K., et al. Anti-apolipoprotein A-1 IgG levels predict coronary artery calcification in obese but otherwise healthy individuals. Mediators Inflamm, 2012, 2012, 243158.
159. 159 Patel, P.J., Khera, A.V., Jafri, K., Wilensky, R.L., Rader, D.J., The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 58 (2011), 2068–2075.
160. 160 Ansell, B.J., Navab, M., Hama, S., et al. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003), 2751–2756.
161. 161 Miyamoto-Sasaki, M., Yasuda, T., Monguchi, T., et al. Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients. J Atheroscler Thromb 20 (2013), 708–716.
162. 162 Guerin, M., Egger, P., Soudant, C., et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 163 (2002), 287–296.
163. 163 Niesor, E.J., Schwartz, G.G., Perez, A., et al. Statin-induced decrease in ATP-binding cassette transporter A1 expression via microRNA33 induction may counteract cholesterol efflux to high-density lipoprotein. Cardiovasc Drugs Ther 29 (2015), 7–14.
164. 164 Ginsberg, H.N., Reyes-Soffer, G., Niacin: a long history, but a questionable future. Curr Opin Lipidol 24 (2013), 475–479.
165. 165 Yadav, R., Liu, Y., Kwok, S., et al. Effect of extended-release niacin on high-density lipoprotein (HDL) functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin-treated patients. J Am Heart Assoc, 4, 2015, e001508.
166. 166 Green, P.S., Vaisar, T., Pennathur, S., et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 118 (2008), 1259–1267.
167. 167 Sorrentino, S.A., Besler, C., Rohrer, L., et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 121 (2010), 110–122.
168. 168 Gomaraschi, M., Ossoli, A., Adorni, M.P., et al. Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome. Vascul Pharmacol 74 (2015), 80–86.
169. 169 Yvan-Charvet, L., Kling, J., Pagler, T., et al. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol 30 (2010), 1430–1438.
170. 170 Franceschini, G., Favari, E., Calabresi, L., et al. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients. J Clin Lipidol 7 (2013), 414–422.
171. 171 Khera, A.V., Patel, P.J., Reilly, M.P., Rader, D.J., The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality. J Am Coll Cardiol 62 (2013), 1909–1910.
172. 172 Taylor, A.J., Villines, T.C., Stanek, E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 361 (2009), 2113–2122.
173. 173 Boden, W.E., Probstfield, J.L., Anderson, T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365 (2011), 2255–2267.
174. 174 Landray, M.J., Haynes, R., Hopewell, J.C., et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 371 (2014), 203–212.
175. 175 Keene, D., Price, C., Shun-Shin, M.J., Francis, D.P., Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. BMJ, 349, 2014, g4379.
176. 176 Keech, A., Simes, R.J., Barter, P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005), 1849–1861.
177. 177 ACCORD Study Group, Ginsberg, H.N., Elam, M.B., et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362 (2010), 1563–1574.
178. 178 Catapano, A.L., Farnier, M., Foody, J.M., et al. Combination therapy in dyslipidemia: where are we now?. Atherosclerosis 237 (2014), 319–335.
179. 179 Khera, A.V., Millar, J.S., Ruotolo, G., Wang, M.D., Rader, D.J., Potent peroxisome proliferator-activated receptor-alpha agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J 36 (2015), 3020–3022.
180. 180 Triolo, M., Annema, W., de Boer, J.F., Tietge, U.J., Dullaart, R.P., Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 44 (2014), 240–248.
181. 181 Guerin, M., Le Goff, W., Frisdal, E., et al. Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux. J Clin Endocrinol Metab 88 (2003), 3738–3746.
182. 182 Franceschini, G., Calabresi, L., Colombo, C., et al. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. Atherosclerosis 195 (2007), 385–391.
183. 183 Fournier, N., Tuloup-Minguez, V., Pourci, M.L., et al. Fibrate treatment induced quantitative and qualitative HDL changes associated with an increase of SR-BI cholesterol efflux capacities in rabbits. Biochimie 95 (2013), 1278–1287.
184. 184 Maranghi, M., Hiukka, A., Badeau, R., et al. Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy. Atherosclerosis 219 (2011), 259–265.
185. 185 Rotllan, N., Llaverias, G., Julve, J., et al. Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo. Biochim Biophys Acta 1811 (2011), 104–110.
186. 186 Paragh, G., Seres, I., Harangi, M., et al. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease. Diabetes Metab 29 (2003), 613–618.
187. 187 Phuntuwate, W., Suthisisang, C., Koanantakul, B., et al. Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels. Atherosclerosis 196 (2008), 122–128.
188. 188 Nissen, S.E., Tardif, J.C., Nicholls, S.J., et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356 (2007), 1304–1316.
189. 189 Nicholls, S.J., Tuzcu, E.M., Brennan, D.M., Tardif, J.C., Nissen, S.E., Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation 118 (2008), 2506–2514.
190. 190 Barter, P.J., Caulfield, M., Eriksson, M., et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357 (2007), 2109–2122.
191. 191 Cannon, C.P., Shah, S., Dansky, H.M., et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363 (2010), 2406–2415.
192. 192 Brinton, E.A., Kher, U., Shah, S., et al. Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. J Clin Lipidol 9 (2015), 65–71.
193. 193 Curb, J.D., Abbott, R.D., Rodriguez, B.L., et al. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J Lipid Res 45 (2004), 948–953.
194. 194 Koropatnick, T.A., Kimbell, J., Chen, R., et al. A prospective study of high-density lipoprotein cholesterol, cholesteryl ester transfer protein gene variants, and healthy aging in very old Japanese-American men. J Gerontol A Biol Sci Med Sci 63 (2008), 1235–1240.
195. 195 Barzilai, N., Atzmon, G., Schechter, C., et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290 (2003), 2030–2040.
196. 196 Soerensen, M., Dato, S., Tan, Q., et al. Evidence from case-control and longitudinal studies supports associations of genetic variation in APOE, CETP, and IL6 with human longevity. Age (Dordr) 35 (2013), 487–500.
197. 197 Zhong, S., Sharp, D.S., Grove, J.S., et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 97 (1996), 2917–2923.
198. 198 Hirano, K., Yamashita, S., Kuga, Y., et al. Atherosclerotic disease in marked hyperalphalipoproteinemia. Combined reduction of cholesteryl ester transfer protein and hepatic triglyceride lipase. Arterioscler Thromb Vasc Biol 15 (1995), 1849–1856.
199. 199 Thompson, A., Di Angelantonio, E., Sarwar, N., et al. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. JAMA 299 (2008), 2777–2788.
200. 200 Kathiresan, S., Will cholesteryl ester transfer protein inhibition succeed primarily by lowering low-density lipoprotein cholesterol? Insights from human genetics and clinical trials. J Am Coll Cardiol 60 (2012), 2049–2052.
201. 201 Wu, Z., Lou, Y., Qiu, X., et al. Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach. BMC Med Genet, 15, 2014, 118.
202. 202 Ritsch, A., Scharnagl, H., Eller, P., et al. Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Circulation 121 (2010), 366–374.
203. 203 Khera, A.V., Wolfe, M.L., Cannon, C.P., Qin, J., Rader, D.J., On-statin cholesteryl ester transfer protein mass and risk of recurrent coronary events (from the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 [PROVE IT-TIMI 22] study). Am J Cardiol 106 (2010), 451–456.
204. 204 de Vries-van der Weij, J., Zadelaar, S., Toet, K., et al. Human CETP aggravates atherosclerosis by increasing VLDL-cholesterol rather than by decreasing HDL-cholesterol in APOE*3-Leiden mice. Atherosclerosis 206 (2009), 153–158.
205. 205 Plump, A.S., Masucci-Magoulas, L., Bruce, C., et al. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterioscler Thromb Vasc Biol 19 (1999), 1105–1110.
206. 206 Rittershaus, C.W., Miller, D.P., Thomas, L.J., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000), 2106–2112.
207. 207 Okamoto, H., Yonemori, F., Wakitani, K., et al. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 406 (2000), 203–207.
208. 208 Morehouse, L.A., Sugarman, E.D., Bourassa, P.A., et al. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits. J Lipid Res 48 (2007), 1263–1272.
209. 209 Sugano, M., Makino, N., Sawada, S., et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 273 (1998), 5033–5036.
210. 210 Yvan-Charvet, L., Matsuura, F., Wang, N., et al. Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol 27 (2007), 1132–1138.
211. 211 Bellanger, N., Julia, Z., Villard, E.F., et al. Functionality of postprandial larger HDL2 particles is enhanced following CETP inhibition therapy. Atherosclerosis 221 (2012), 160–168.
212. 212 Catalano, G., Julia, Z., Frisdal, E., et al. Torcetrapib differentially modulates the biological activities of HDL2 and HDL3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 29 (2009), 268–275.
213. 213 Tchoua, U., D'Souza, W., Mukhamedova, N., et al. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport. Cardiovasc Res 77 (2008), 732–739.
214. 214 Niesor, E.J., Magg, C., Ogawa, N., et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-beta-HDL formation and increases reverse cholesterol transport. J Lipid Res 51 (2010), 3443–3454.
215. 215 Ballantyne, C.M., Miller, M., Niesor, E.J., et al. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study. Am Heart J 163 (2012), 515–521 521.e1–3.
216. 216 Ray, K.K., Ditmarsch, M., Kallend, D., et al. The effect of cholesteryl ester transfer proteisn inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J 35 (2014), 1792–1800.
217. 217 Briand, F., Thieblemont, Q., Muzotte, E., et al. Anacetrapib and dalcetrapib differentially alters HDL metabolism and macrophage-to-feces reverse cholesterol transport at similar levels of CETP inhibition in hamsters. Eur J Pharmacol 740 (2014), 135–143.
218. 218 Riwanto, M., Deanfield, J., Manz, J., et al. Vascular effects of high-density lipoprotein after CETP inhibition with dalcetrapib in patients with stable coronary disease or an acute coronary syndrome. AHA Sessions, 2012.
219. 219 Tardif, J.C., Rheaume, E., Lemieux Perreault, L.P., et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet 8 (2015), 372–382.
220. 220 Castro-Perez, J., Briand, F., Gagen, K., et al. Anacetrapib promotes reverse cholesterol transport and bulk cholesterol excretion in Syrian golden hamsters. J Lipid Res 52 (2011), 1965–1973.
221. 221 Han, S., Levoci, L., Fischer, P., et al. Inhibition of cholesteryl ester transfer protein by anacetrapib does not impair the anti-inflammatory properties of high density lipoprotein. Biochim Biophys Acta 1831 (2013), 825–833.
222. 222 Uehara, Y., Chiesa, G., Saku, K., High-density lipoprotein-targeted therapy and apolipoprotein A-I mimetic peptides. Circ J 79 (2015), 2523–2528.
223. 223 Stoekenbroek, R.M., Stroes, E.S., Hovingh, G.K., ApoA-I mimetics. Handb Exp Pharmacol 224 (2015), 631–648.
224. 224 Tardif, J.C., Gregoire, J., L'Allier, P.L., et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 297 (2007), 1675–1682.
225. 225 Spieker, L.E., Sudano, I., Hurlimann, D., et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 105 (2002), 1399–1402.
226. 226 Bisoendial, R.J., Hovingh, G.K., Levels, J.H., et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 107 (2003), 2944–2948.
227. 227 Drew, B.G., Duffy, S.J., Formosa, M.F., et al. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 119 (2009), 2103–2111.
228. 228 Patel, S., Drew, B.G., Nakhla, S., et al. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. J Am Coll Cardiol 53 (2009), 962–971.
229. 229 Hoang, A., Drew, B.G., Low, H., et al. Mechanism of cholesterol efflux in humans after infusion of reconstituted high-density lipoprotein. Eur Heart J 33 (2012), 657–665.
230. 230 Huang, Y., von Eckardstein, A., Assmann, G., Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma. Arterioscler Thromb 13 (1993), 445–458.
231. 231 Gille, A., Easton, R., D'Andrea, D., Wright, S.D., Shear, C.L., CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects. Arterioscler Thromb Vasc Biol 34 (2014), 2106–2114.
232. 232 Ibanez, B., Giannarelli, C., Cimmino, G., et al. Recombinant HDL(Milano) exerts greater anti-inflammatory and plaque stabilizing properties than HDL(wild-type). Atherosclerosis 220 (2012), 72–77.
233. 233 Nissen, S.E., Tsunoda, T., Tuzcu, E.M., et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 290 (2003), 2292–2300.
234. 234 Kempen, H.J., Gomaraschi, M., Bellibas, S.E., et al. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys. J Lipid Res 54 (2013), 2341–2353.
235. 235 Kempen, H.J., Schranz, D.B., Asztalos, B.F., et al. Incubation of MDCO-216 (ApoA-IMilano/POPC) with human serum potentiates ABCA1-mediated cholesterol efflux capacity, generates new prebeta-1 HDL, and causes an increase in HDL size. J Lipids, 2014, 2014, 923903.
236. 236 Barbaras, R., Non-clinical development of CER-001. Front Pharmacol, 6, 2015, 220.
237. 237 Kootte, R.S., Smits, L.P., van der Valk, F.M., et al. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res 56 (2015), 703–712.
238. 238 Hovingh, G.K., Smits, L.P., Stefanutti, C., et al. The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: the Modifying Orphan Disease Evaluation (MODE) study. Am Heart J 169 (2015), 736–742.e1.
239. 239 Tardif, J.C., Ballantyne, C.M., Barter, P., et al. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J 35 (2014), 3277–3286.
240. 240 O'Neill, F., McLoughlin, E., Riwanto, M., et al. Reproducibility and biological variability of HDL's vascular functional assays. Atherosclerosis 241 (2015), 588–594.
241. 241 Morrow, D.A., de Lemos, J.A., Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115 (2007), 949–952.
242. 242 Vasan, R.S., Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 113 (2006), 2335–2362.
243. 243 Yamashita, S., Masuda, D., Matsuzawa, Y., Did we abandon probucol too soon?. Curr Opin Lipidol 26 (2015), 304–316.
244. 244 Wu, F.C., von Eckardstein, A., Androgens and coronary artery disease. Endocr Rev 24 (2003), 183–217.